2026 年至 2035 年男性性腺功能低下症的市场机会、成长要素、产业趋势分析与预测。

预计到 2025 年，全球男性性腺功能低下症市场价值将达到 42 亿美元，并有望以 5.4% 的复合年增长率成长，到 2035 年达到 71 亿美元。

医疗机构、政府部门和私人组织正加强，致力于推广男性性腺功能低下症症是指睪丸无法产生足够的睪固酮或功能异常，进而导致生理、性功能和心理方面的併发症。睪固酮替代疗法 (TRT) 的进步正在改变疾病管理方式，提供更安全、更有效、更方便的治疗方案。改良的配方、个人化的治疗方案、创新的给药系统以及与数位健康工具的整合，使患者能够以最小的副作用维持稳定的荷尔蒙水平。随着临床意识的提高和先进治疗方法的引入，市场正受益于患者疗效的改善、医疗基础设施的加强以及人们对睾酮缺乏症长期管理策略接受度的提高。

预计到2025年，睪固酮替代疗法（TRT）市场规模将达到33亿美元，并有望以5.5%的复合年增长率稳定成长至2035年。 TRT在恢復正常睪固酮水平方面发挥着至关重要的作用，从而改善性功能、性慾、勃起功能和整体健康状况。除了性健康之外，睪酮还会影响脂肪分布和代谢，低水平的睪酮会导致内臟脂肪堆积。支持性的医疗政策和法律规范正在扩大患者获得TRT的机会，并促进对新治疗方法的探索。随着医生越来越注重精准的剂量控制和个人化治疗，先进睪酮疗法的应用也进一步推动了市场成长。

预计到2025年，注射类药物市场规模将达23亿美元，占市占率的55.3%。注射用睪酮疗法，例如庚酸睪酮和环戊丙酸睪酮，能够稳定荷尔蒙水平，减少情绪波动、疲劳和性慾减退。精准的剂量调整使临床医生能够为每位患者制定个人化的治疗方案，在最大限度地提高疗效的同时，最大限度地减少副作用。由于其可靠性、疗效稳定和临床适用性，注射类药物仍然是患者和医疗专业人员的首选。

预计2025年，北美男性性腺功能低下症市场规模将达18亿美元，2035年将达33亿美元。该地区的强劲市场地位得益于男性健康意识的提高、睾酮替代疗法（TRT）的广泛应用以及先进的诊断服务。成熟的医疗保健体系，包括专业的内分泌和泌尿系统诊所，以及不断扩展的远端医疗TRT项目，正在加速早期诊断和治疗的启动。美国和加拿大受益于全面的荷尔蒙检测覆盖、强大的製药公司网络以及先进的给药方式，例如经皮凝胶、长效注射和植入式植入。这些因素共同巩固了该地区市场的主导地位。

目录

第一章：调查方法和范围

第二章执行摘要

第三章业界考察

• 生态系分析
• 影响产业的因素
  • 促进因素
    • 意识提高和诊断数量增加
    • 性腺功能减退症发生率增加
    • 睾酮替代疗法的进展
    • 男性健康和保健计划的增长
  • 产业潜在风险与挑战
    • 安全隐忧和副作用
    • 严格遵守规章制度
  • 市场机会
    • 远距远端医疗TRT平台的扩展
• 成长潜力分析
• 监理情势
• 技术格局
  • 目前技术
    • 注射以睪固酮製剂作为主要标准治疗
    • 扩大经皮凝胶和贴片的应用，以实现稳定的每日荷尔蒙传递。
  • 新兴技术
    • 人们对长效缓释疗法的兴趣日益浓厚。
    • 下一代口服睪固酮製剂的研发
    • 微针和经皮给药系统的进展
• 未来市场趋势
• 投资和资金筹措趋势
• 管道分析
• 波特五力分析
• PESTEL 分析

第四章 竞争情势

• 介绍
• 企业市占率分析
  • 世界
  • 北美洲
  • 欧洲
  • 亚太地区
• 企业矩阵分析
• 主要市场公司的竞争分析
• 竞争定位矩阵
• 主要进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 业务拓展计划

第五章 市场估计与预测：依治疗方法，2022-2035年

• 睾酮替代疗法
• 荷尔蒙疗法

第六章 市场估计与预测：依给药途径划分，2022-2035年

• 注射药物
• 外用
• 口服

第七章 市场估计与预测：依应用领域划分，2022-2035年

• 卡门氏症候群
• 柯林菲特氏症
• 脑下垂体疾病
• 其他用途

第八章 市场估计与预测：依地区划分，2022-2035年

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国

第九章：公司简介

• Antares Pharma
• Acerus Pharmaceuticals
• Aspen Pharmacare
• Aurobindo Pharmaceutical
• Bayer AG
• Besins Healthcare
• Bharat Serums and Vaccines
• Eli Lilly and Company
• Endo Pharmaceuticals
• Lupin Pharmaceuticals
• Merck
• Simple Pharma
• Pfizer
• Teva Pharmaceutical Industries
• Viatris

The Global Male Hypogonadism Market was valued at USD 4.2 billion in 2025 and is estimated to grow at a CAGR of 5.4% to reach USD 7.1 billion by 2035.

Growing initiatives by healthcare providers, government agencies, and private organizations are focusing on promoting early diagnosis, preventive care, and education around male hypogonadism. This condition occurs when the testicles fail to produce sufficient testosterone or function properly, leading to physical, sexual, and psychological complications. Advancements in testosterone replacement therapy (TRT) are transforming disease management through safer, more effective, and convenient treatment options. Improved formulations, personalized treatment plans, innovative delivery systems, and integration with digital health tools are helping patients maintain stable hormone levels while minimizing side effects. With rising clinical awareness and the adoption of advanced therapeutic options, the market is benefiting from enhanced patient outcomes, stronger healthcare infrastructure, and increased acceptance of long-term management strategies for testosterone deficiency.

The testosterone replacement therapy segment reached USD 3.3 billion in 2025 and is expected to experience steady growth at a CAGR of 5.5% through 2035. TRT plays a critical role in restoring normal testosterone levels, which improves sexual health, libido, erectile function, and overall well-being. Beyond sexual health, testosterone impacts fat distribution and metabolism, making low levels a contributor to increased visceral fat accumulation. Supportive healthcare policies and regulatory frameworks have expanded patient access to TRT and incentivized research into new therapies. As physicians increasingly focus on precision dosing and personalized management, the adoption of advanced testosterone therapies continues to strengthen market growth.

The injectable segment reached USD 2.3 billion in 2025, representing 55.3% share. Injectable testosterone therapies, such as enanthate and cypionate, provide stable hormone levels, reducing mood fluctuations, fatigue, and libido variations. The ability to precisely adjust dosages allows clinicians to tailor treatment plans for individual patients, optimizing efficacy while minimizing side effects. Injectable formulations remain a preferred option for patients and healthcare providers due to their proven reliability, consistent results, and adaptability in clinical practice.

North America Male Hypogonadism Market accounted for USD 1.8 billion in 2025 and is expected to reach USD 3.3 billion by 2035. The region's strong position is supported by high awareness of men's health, widespread use of TRT, and advanced diagnostic services. Mature healthcare ecosystems, including specialized endocrinology and urology clinics, along with expanding telehealth TRT programs, have facilitated early diagnosis and treatment adoption. The U.S. and Canada benefit from comprehensive hormone testing coverage, robust pharmaceutical presence, and the availability of advanced delivery methods, including transdermal gels, long-acting injectables, and subcutaneous implants. These factors collectively strengthen the market's dominance in the region.

Key players in the Global Male Hypogonadism Market include Antares Pharma, Acerus Pharmaceuticals, Aspen Pharmacare, Aurobindo Pharmaceutical, Bayer AG, Besins Healthcare, Bharat Serums and Vaccines, Eli Lilly and Company, Endo Pharmaceuticals, Lupin Pharmaceuticals, Merck, Simple Pharma, Pfizer, Teva Pharmaceutical Industries, and Viatris. Companies in the Male Hypogonadism Market are pursuing multiple strategies to reinforce their market presence and competitive positioning. They are focusing on developing innovative testosterone formulations with improved bioavailability, extended-release profiles, and patient-friendly delivery systems to enhance treatment adherence. Many are investing in R&D to create personalized therapies tailored to individual hormonal profiles. Strategic partnerships with healthcare providers, clinics, and telehealth platforms are expanding distribution networks and patient access. Additionally, marketing campaigns and educational programs are increasing awareness of men's health issues, supporting early diagnosis and adoption of therapies. Regulatory compliance and engagement with advocacy initiatives further strengthen their credibility and market footprint.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
• 1.10 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Business trends
  • 2.2.1 Treatment type trends
  • 2.2.2 Route of administration trends
  • 2.2.3 Application trends
  • 2.2.4 Regional trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing awareness and diagnosis
    • 3.2.1.2 Rising incidence of hypogonadism
    • 3.2.1.3 Advancements in testosterone replacement therapies
    • 3.2.1.4 Growth in men’s health and wellness programs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Safety concerns and side effects
    • 3.2.2.2 Stringent regulatory compliance
  • 3.2.3 Market opportunity
    • 3.2.3.1 Expansion of telemedicine-based TRT platforms
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technological landscape
  • 3.5.1 Current technology
    • 3.5.1.1 Injectable testosterone formulations as the primary standard of care
    • 3.5.1.2 Growing adoption of transdermal gels and patches for stable daily hormone delivery
  • 3.5.2 Emerging technology
    • 3.5.2.1 Growing focus towards long-acting, controlled-release therapies
    • 3.5.2.2 Development of next-generation oral testosterone formulations
    • 3.5.2.3 Advancements in microneedle and transdermal delivery systems
• 3.6 Future market trends
• 3.7 Investment and funding landscape
• 3.8 Pipeline analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
  • 4.2.4 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Testosterone replacement therapy
• 5.3 Gonadotropin therapy

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Injectable
• 6.3 Topical
• 6.4 Oral

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Kallmann syndrome
• 7.3 Klinefelter syndrome
• 7.4 Pituitary disorders
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Antares Pharma
• 9.2 Acerus Pharmaceuticals
• 9.3 Aspen Pharmacare
• 9.4 Aurobindo Pharmaceutical
• 9.5 Bayer AG
• 9.6 Besins Healthcare
• 9.7 Bharat Serums and Vaccines
• 9.8 Eli Lilly and Company
• 9.9 Endo Pharmaceuticals
• 9.10 Lupin Pharmaceuticals
• 9.11 Merck
• 9.12 Simple Pharma
• 9.13 Pfizer
• 9.14 Teva Pharmaceutical Industries
• 9.15 Viatris